Sugi Predict

Sugi Predict / Compounds / SCHEMBL2467470

SCHEMBL2467470

SCHEMBL2467470

NNC(=S)Nc1cccc(C(F)(F)F)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 1.00
▸ MAPT P10636 8/20 0.76
▸ ALDH1A1 P00352 6/20 0.76
▸ GAA P10253 5/20 0.76
▸ NPSR1 Q6W5P4 5/20 0.76
▸ TDP1 Q9NUW8 3/20 0.76
▸ SMN1; SMN2 Q16637 3/20 0.68
▸ MEN1 O00255 2/20 0.68
▸ KMT2A Q03164 2/20 0.68
▸ CYP1A2 P05177 1/20 0.68
▸ CYP3A4 P08684 1/20 0.68
▸ CYP2D6 P10635 1/20 0.68
▸ CYP2C19 P33261 1/20 0.68
▸ L3MBTL1 Q9Y468 3/20 0.66
▸ KDM4E B2RXH2 2/20 0.66
▸ LMNA P02545 3/20 0.62
▸ HTT P42858 2/20 0.61
▸ TP53 P04637 1/20 0.61
▸ XBP1 P17861 1/20 0.61
▸ S1PR3 Q99500 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175227 0.90 MAPT (0.86) IDO1MAPTALDH1A1GAANPSR1
SCHEMBL22567938 0.85 MAPT (0.78) IDO1MAPTALDH1A1GAANPSR1
SCHEMBL22567749 0.85 MAPT (0.78) IDO1MAPTALDH1A1GAANPSR1
SCHEMBL12412637 0.83 ALDH1A1 (0.76) IDO1MAPTALDH1A1GAANPSR1
SCHEMBL230618 0.83 IDO1 (0.71) IDO1MAPTALDH1A1GAANPSR1
SCHEMBL6816145 0.83 IDO1 (0.70) IDO1MAPTALDH1A1GAANPSR1
SCHEMBL5438060 0.82 IDO1 (0.70) IDO1MAPTALDH1A1GAANPSR1
SCHEMBL22024982 0.82 SMN1; SMN2 (0.75) IDO1MAPTALDH1A1GAANPSR1
SCHEMBL9724981 0.81 IDO1 (0.69) IDO1MAPTALDH1A1GAANPSR1
SCHEMBL6985227 0.81 IDO1 (0.69) IDO1MAPTALDH1A1GAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010896-A Bicyclol derivative, pharmaceutical composition thereof, preparation method and application thereof 中国医学科学院药物研究所 2026-05-12 — — CN disclosed
WO-2025046420-A1 COMPOUND TARGETING EGR-1 AND USE THEREOF FOR TREATMENT OF ATOPIC DERMATITIS 주식회사 아제라메디 2025-03-06 — — WO disclosed
CN-114634502-B 3-Aryl substituted thiazolidine-4-ketone-2-methylene hydrazono methylene-1H-indole derivative and preparation method thereof 复旦大学 2024-05-24 — — CN disclosed
CN-114634502-A 3-aryl substituted thiazolidine-4-ketone-2-ylidenehydrazonomethylene-1H-indole derivatives and preparation method thereof 复旦大学 2022-06-17 — — CN disclosed
EP-2550266-B1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTICS SOLUTIONS INC (US) 2018-05-09 — — EP disclosed
EP-2550266-B1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTICS SOLUTIONS INC (US) 2018-05-09 — — EP disclosed
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 — — US disclosed
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 — — US disclosed
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 — — US disclosed
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 — — US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 — — US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 — — US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 — — US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 — — US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 — — US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 — — US disclosed
EP-2550266-A2 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION Amitech Therapeutics Solutions, Inc. (US) 2013-01-30 — — EP disclosed
WO-2011119894-A2 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION KINAGEN, INC (US) 2011-09-29 — — WO disclosed
WO-2011119894-A2 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION KINAGEN, INC (US) 2011-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 IDO1 3958/4885MAPT 4114/4885ALDH1A1 3693/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 IDO1 3958/4885MAPT 4114/4885ALDH1A1 3693/4885
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 IDO1 3958/4885MAPT 4114/4885ALDH1A1 3693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.